According to the Financial Communication APP, on October 25, the China Securities Regulatory Commission released the "Overseas Issuance and Listing Filing Status Table of Domestic Enterprises (Initial Public Offering and Full Circulation) (as of October 24, 2024)," in which Elpiscience Biopharmaceuticals, Inc. (Kewei Pharmaceutical Group) was listed as "supplementary materials" in the listing filing status with the China Securities Regulatory Commission. As disclosed by the Hong Kong Stock Exchange on June 27, Elpiscience Biopharmaceuticals, Inc. (Kewei Pharmaceutical Group) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citic Securities as its exclusive sponsor.

The prospectus shows that Kewei Pharmaceutical Group is a clinical-stage biomedical company established in 2017, dedicated to innovating tumor treatment globally through next-generation therapies. With a profound understanding of the tumor microenvironment (TME) and pioneering research, the company aims to cover innovative and promising targets and pathways in cancer biology with a systematic approach, leading the next wave of innovation in immuno-oncology.

In terms of finances, in 2022 and 2023, Kewei Pharmaceutical Group's research and development costs were approximately 0.351 billion yuan and 0.108 billion yuan respectively; while the total losses and comprehensive losses for the same periods were approximately 0.771 billion yuan and 0.853 billion yuan.